Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(4), 1850-1857 | ISSN:2251-6727

Transforming Drug Discovery and Development:The Impact of Artificial Intelligence

Santosh patnaik[1] ,Manoranjan Sahu[2*] , Budumuru Padmasri[3],Prasanth Damarasingu[4], Durga Madhab Nayak[5] , Prof. Rajeshree Panigrahi[6] ,M.Akiful Haque[7], Saswati Panigrahi[8]

[1]Pharmaceutical analysis and quality assurance, Royal College of pharmacy and health sciences , Berhampur, odisha 760002
[2*] Principal, School of pharmaceutical Education and Research, Berhampur University, 76007,Odisha.
[3]Dept of Pharmaceutical technology, Sri Venkateswara College of Pharmacy, Etcherla, Srikakulam, Andhra Pradesh-532410
[4]Dept.of Pharmacology, School of Pharmacy, Centurion University of Technology and Management, Gopalpur, Balasore
[5]College of Pharmaceutical Science, Mohuda, Berhampur,Affiliated to Odisha University of Health Sciences
[6]Royal College of Pharmacy and Health Sciences, Andhapasara Road, Berhampur-760002
[7]School of Pharmacy,Anurag University , Venkatapur, Hyderabad 500088
[8]St. John Institute of Pharmacy and Research, Vevoor, Manor Road, Palghar (E), District Palghar, Palghar, Maharashtra 401404

(Received: 02 September 2023 Revised: 14 October Accepted: 07 November)

KEYWORDS
Artificial intelligence ,Algorithms,clinical trials,monitoring,drugs

Abstract
Artificial intelligence (AI) is revolutionizing the drug development process, transforming the entire process. AI can help researchers find drug candidates faster, conduct clinical trials more efficiently, improve manufacturing processes, and expand market access options. It can speed up the first phases of drug discovery by facilitating quick screening of candidate compounds by anticipating interactions between molecules and target proteins. AI also plays a significant role in the successful repurposing of drugs by finding new therapeutic applications for medications approved for other purposes.Predictive toxicology is another area where AI is having a major impact. By predicting probable toxicities and side effects of drug candidates using AI, late-stage failures are reduced and patient safety ensured. AI is also reshaping trial methodology and patient recruiting in clinical trials, reducing costs and improving success rates.AI also helps the pharmaceutical industry deal with increasingly complicated regulatory environments by deciphering and analyzing regulatory documents and recommendations to ensure conformity with ever-changing norms. This capacity accelerates the regulatory approval process, allowing the introduction of new pharmaceuticals to the market.Despite the challenges, AI has had far-reaching and complex effects on the pharmaceutical industry. With the help of AI, the pharmaceutical industry can speed up the discovery of new drug ideas, improve the effectiveness of clinical trials, streamline production, and hone its approach to market access. The payoff for patients and the pharmaceutical business could be enormous.

Introduction

Since the beginning of the pharmaceutical industry, one of its primary goals has been to discover disease-fighting medicines and treatment methods that can significantly advance the state of human health. However, this path has been riddled with difficulties, such as the high expenditures and extended timeframes associated with the discovery of new drugs, as well as the high attrition rates of potential candidates experienced during clinical trials. In recent years, a potentially has surfaced in order to address these difficulties, and its name is artificial intelligence (AI). The introduction of artificial intelligence (AI) into the processes of drug discovery and development marks the beginning of a revolutionary age that holds the potential to change the industry and speed up the delivery of

Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(4), 1850-1857 | ISSN:2251-6727

novel medications to patients all over the world[1,2].This study investigates the significant influence that AI has had on the pharmaceutical industry, providing an in-depth analysis of the uses and implications of AI in this field[3,4]. Artificial intelligence is revolutionising every aspect of the drug development pipeline, beginning with the early phases of target identification and drug discovery and continuing all the way through clinical trials, manufacturing, regulatory compliance, and market access. It is not only a technological advancement; rather, it symbolises a paradigm shift in the way pharmaceutical research is carried out. As a result, the landscape will be profoundly altered, and new opportunities for innovation will become available.

1. The Conventional Method of Drug Exploration and Development

It is vital to gain an understanding of the obstacles that are inherent in the conventional method of drug discovery before going into the myriad of ways in which AI is revolutionising drug research and development.The process of drug development has traditionally been one that was time-consuming and resource-demanding[5,6,7]. It usually starts with the identification of a biological target linked with a certain disease, such as a protein or gene that is involved in the progression of the disease. The next step for the researchers is to seek for molecules, which are often tiny organic compounds, that have the potential to interact with the target and modulate its activity in a way that is useful from a therapeutic standpoint[8]. Target-based drug development is a procedure that comprises a succession of labor-intensive steps. Some of these steps include high-throughput screening of chemical libraries, lead optimisation, and preclinical testing.The high rate of unsuccessful drug candidates is one of the most serious obstacles presented by traditional methods of drug discovery[9]. The subsequent stages of the research process, notably clinical testing, are notoriously difficult for many drugs, even those that have shown initial signs of promise[10,11]. This attrition is due to a number of variables, including unanticipated toxicity, a lack of efficacy in human patients, and manufacturing challenges[12].In addition, the usual method of finding new drugs is a lengthy and pricey procedure. From the conception of a new drug all the way through to its eventual approval for sale on the market can take upwards of a decade and tens of billions of dollars[13]. This drawn-out timeline not only prevents patients from gaining access to potentially life-saving treatments, but it also drives up the cost of healthcare and hinders innovation.

Figure-1 Application of artificial intelligence in pharma sector.

2. The Development of Computer-Generated Intelligence

The use of artificial intelligence (AI) to the processes of drug discovery and development is a disruptive force that possesses the ability to address many of the flaws of the conventional method[14]. Machine learning, deep learning, natural language processing, and robotics are only few of the technologies that fall under the umbrella of artificial intelligence (AI), which can be loosely defined as the emulation of human intellect in computers[16]. The entire drug development process is undergoing a transformation thanks to the application of these AI techniques.

3. The Use of AI to Hasten the Process of Drug Discovery

The acceleration of the early stages of candidate identification and validation is one of the applications of artificial intelligence in drug discovery that has the potential to have the greatest impact [17]. The ability of AI algorithms to analyse enormous databases of biological and chemical information more quickly and thoroughly than human researchers is a significant advantage of using AI [18]. Because of its analytical prowess, AI is able to forecast possible medication candidates by modelling their interactions with target proteins and reviewing the safety profiles of the potential options.For example, algorithms for machine learning can sort through enormous databases of

Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(4), 1850-1857 | ISSN:2251-6727

chemical structures and data on biological activity to find molecules that have the necessary qualities. They are able to make predictions about which compounds are likely to bind to a certain target and regulate the activity of that target in a way that is useful to therapeutics[19]. This cuts down greatly on the amount of time and resources needed for lead finding.In addition, AI-driven methods are quite helpful in both the process of identifying targets and validating those targets. Through the examination of a wide variety of data sources, such as genomes, proteomics, and clinical data, artificial intelligence is able to identify possible disease targets that have a greater chance of being successful[20]. This method, which is driven by data, increases the possibility of identifying targets that are both physiologically relevant to the disease and capable of being treated therapeutically.

4. The Repurposing of Drugs and the Use of AI

In addition to the development of innovative drugs, artificial intelligence is also proving to be an invaluable tool in the field of drug repurposing. Finding new therapeutic applications for medications already on the market that were initially created to treat a variety of conditions is an example of drug repurposing[21]. This strategy provides a number of benefits, including shortened timetables for development and decreased overall development expenses.By exploiting its ability to conduct in-depth analyses of chemical characteristics and interactions, AI performs exceptionally well in the field of drug repurposing [22]. AI algorithms have the ability to find previously unrecognised therapeutic options by analysing the molecular properties of licenced medications and their interactions with biological systems [23].For instance, a medicine that was originally created to treat a certain kind of cancer may later be repurposed to treat another kind of cancer or an illness that is unrelated to cancer [24]. This strategy of repurposing existing pharmaceuticals can give them a new lease on life, extending the variety of conditions for which they are useful, and potentially helping a greater number of people [25].

5. A Predictive Approach to Toxicology and Safety Evaluation

During the drug development process, one of the most important goals is to confirm that potential treatments are safe [26]. Late-stage failures caused by unexpected toxicities can be both financially burdensome and damaging to the health of the patient [27]. Artificial intelligence is playing an important part in predictive toxicology, where it is helping to uncover potential safety risks at an earlier stage in the research process [28].The probable toxicity of new drug candidates can be predicted using artificial intelligence algorithms that have been trained on huge datasets of known toxicities and adverse events [29]. In order to determine the possibility of bad consequences, these models evaluate the chemical structures of compounds, the biological interactions between those compounds, and the historical data on safety [30]. Because of this potential for prediction, researchers are able to prioritise compounds that have favourable safety profiles, which helps to reduce the likelihood of late-stage failures.In addition to this, AI has the potential to improve our comprehension of the mechanisms that underlie drug-induced toxicity [31]. Through the study of molecular pathways and biological networks, artificial intelligence might unearth insights into the reasons why particular drugs may lead to detrimental effects in certain patient populations. Using this information to inform drug design and dosing tactics can help alleviate some of the safety issues [32].

6. Using Artificial Intelligence to Optimise Clinical Trials

Clinical tests are an integral component of the drug development process because they collect crucial information about the effectiveness and tolerability of a medicine in human subjects. On the other hand, clinical studies require a significant investment of both time and resources, and they can take years to finish [33]. The field of clinical trials is ripe for disruption by artificial intelligence, which promises to improve trial design, patient recruitment, and data processing [34].Algorithms that learn via machine experience can examine patient data to locate people who might benefit from participation in clinical trials [35]. AI is able to match individuals with specific trial protocols by taking into account the genetic, demographic, and clinical aspects of a patient. This increases the likelihood of the study being successful [36]. This individualised strategy not only speeds up the process of recruiting patients, but it also increases the possibility of identifying treatment effects in particular subpopulations [37].In addition, AI can help with the design of trials by modelling various

Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(4), 1850-1857 | ISSN:2251-6727

possible outcomes and providing predictions based on those models [38]. Researchers have the opportunity to improve dosage regimens, patient stratification tactics, and endpoint selection by utilising insights given by AI. This data-driven strategy makes clinical trials more effective in terms of both their efficiency and their cost-effectiveness [39].

7. The Optimisation of Drug Formulation and Delivery Systems

AI is not only used in the early stages of drug research; it also plays an important role in optimising drug formulation and delivery. It is possible to improve treatment efficacy and patient compliance by customising drug formulations and delivery methods to the specific characteristics of individual patients . Approaches driven by AI are able to perform analyses of patient data such as genetics, metabolism, and features of disease in order to build personalised medication delivery systems [40]. For this reason, a patient who possesses a certain genetic make-up can need for a specialised drug formulation in order to experience the most beneficial therapeutic results [41]. AI can provide a hand in the process of designing these individualised solutions, which will ensure that each individual patient receives the most beneficial treatment.In addition to this, AI can improve the procedures involved in the production of pharmaceuticals [42]. Automation and real-time quality control that are supported by AI have the potential to improve production efficiency, lower mistake rates, and guarantee quality that is consistent across products. This not only lowers the cost of production but also reduces the amount of variability in drug formulations, which leads to better outcomes for patients [43].

8. Integration of Data and Collaborative Efforts

A distinguishing feature of AI-driven drug discovery and development is the incorporation of a wide variety of data sources [44]. AI technologies are particularly effective at combining and analysing data obtained from a wide variety of sources, like as genomes, proteomics, clinical trials, and electronic health records [45].Because of the integration of these data, researchers are able to get full insights into the mechanisms of disease and the responses of drugs [46]. AI is able to find hidden patterns and associations by connecting the dots between genetic variations, protein interactions, patient features, and clinical outcomes [47]. These discoveries can inform drug development tactics.In addition to this, AI encourages collaboration not only inside research teams but also between research teams and organisations. Researchers are now able to more effectively share data and analyse it, breaking down the silos that have traditionally slowed down the process of discovering new drugs [48]. Platforms for collaborative artificial intelligence make it easier to share observations and discoveries, which speeds up the pace of invention.

9. The Observance of Regulatory Requirements and the Approval of Drugs

The ability to successfully navigate the intricate regulatory landscape is an essential component of medication development. The Food and medication Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe are two examples of regulatory agencies that have severe requirements that must be met by medication developers in order to guarantee the drugs' efficacy and safety [49]. Artificial intelligence can help pharmaceutical companies stay in compliance with increasingly stringent regulatory regulations [50]. Algorithms based on artificial intelligence are able to analyse and interpret complicated regulatory papers and rules, which enables organisations to better align their development strategies with regulatory expectations [51]. This expertise is essential to accelerating the process of regulatory approval, which in turn makes it possible to bring innovative drugs to market more quickly.In addition, AI has the potential to improve the openness and traceability of the processes involved in the development of drugs, which will make regulatory audits and inspections much simpler. AI systems can assist organisations in demonstrating their commitment to quality and safety by assisting in the maintenance of detailed records and the automation of compliance inspections [52].

10. Strategies for Drug Pricing and Gaining Market Access

Considerations relating to both the cost of pharmaceutical items and their availability on the market are complex and multifaceted. AI is proving to be a useful tool in optimising these strategies by performing analyses of market dynamics, patient

Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(4), 1850-1857 | ISSN:2251-6727

demographics, and economics related to healthcare delivery [53].Analyses guided by AI have the potential to provide insights into the most effective pricing methods for pharmaceutical items. Artificial intelligence can assist pharmaceutical businesses in setting pricing that are reflective of the value their products bring to patients and healthcare systems by taking into consideration aspects such as therapeutic value, competition, and the preferences of healthcare payers [54]. In addition, AI can help inform market access plans by identifying key stakeholders, payers, and decision-makers in the healthcare ecosystem. With this information, pharmaceutical businesses are able to better target their market access strategies towards certain patient populations and geographic locations, hence increasing their market penetration and product uptake [55].

11. Challenges and Considerations Regarding Ethical Issues

It is necessary to identify and address the ethical considerations and obstacles connected with the use of artificial intelligence, despite the fact that the potential benefits of AI in drug research and development could be enormous.Data privacy is one of the key considerations when it comes to ethics . Artificial intelligence is dependent on enormous datasets, including as information on patients and biological data. It is of the utmost importance to protect the data's privacy and keep it secure . Finding a happy medium between the need for data access for research and the need to protect the privacy of patients is an ongoing challenge.The existence of prejudice in AI systems is yet another ethical concern. It is possible for erroneous predictions or unequal access to therapies to come from the use of biassed data or automated decision-making processes . In order to ensure that the process of developing new drugs is fair and equitable, researchers and developers need to actively work to discover and reduce bias in AI systems.In addition, regulatory bodies need to adjust in order to keep up with the rapid development of AI technologies . For the purpose of ensuring the secure and productive application of AI in drug discovery and development, well-defined norms and standards are required. A sensitive issue that involves continuous coordination between industry stakeholders and regulatory agencies is striking a balance between the oversight of innovations and the regulatory process .

Conclusion

In summing up, the application of artificial intelligence (AI) to the processes of drug discovery and development constitutes a paradigm shift that ushers in a significant advance for the pharmaceutical sector. AI is helping to speed up the process of identifying potential medication candidates, streamline clinical trials, optimise manufacturing processes, and improve market access tactics. It will radically change the way we approach the creation of novel therapeutics because it is not only a tool but rather a catalyst for invention.Although there are some obstacles to overcome and ethical concerns to take into account, there is a tremendous potential for both patients and the pharmaceutical business to gain from this. AI technologies are on the verge of playing an increasingly significant role in the transformation of drug research and development, which will ultimately improve patient access to breakthrough treatments. The road to harness the full potential of AI in drug development is underway. This journey holds the promise of a future in which the translation of scientific discoveries into life-saving treatments will be quicker, more efficient, and more accessible than it has ever been. It is vital that we manage the ethical and regulatory obstacles with care as we embark on this transformative path. This will ensure that the benefits of AI are realised fairly for all patients and healthcare systems.

Acknowledgement

I would like to express my profound appreciation to all individuals who have made valuable contributions towards the successful culmination of this scientific endeavour. The assistance, mentorship, and motivation provided by you have played a crucial role in determining the outcome of this endeavour.

Conflict of interest

The authors declare that they have no conflict of interest.

Refrences

1. Lamberti, M. J., Wilkinson, M., Donzanti, B. A., Wohlhieter, G. E., Parikh, S., Wilkins, R. G., & Getz, K. (2019). A study on the application and

use of artificial intelligence to support drug development. *Clinical therapeutics*, *41*(8), 1414-1426.
2. Smith, R. G., & Farquhar, A. (2000). The road ahead for knowledge management: an AI perspective. AI magazine, 21(4), 17-17.
3. Lu, Z. X., Qian, P., Bi, D., Ye, Z. W., He, X., Zhao, Y. H., ... & Zhu, Z. L. (2021). Application of AI and IoT in clinical medicine: summary and challenges. Current medical science, 41, 1134-1150.
4. Secinaro, S., Calandra, D., Secinaro, A., Muthurangu, V., & Biancone, P. (2021). The role of artificial intelligence in healthcare: a structured literature review. BMC medical informatics and decision making, 21, 1-23.
5. Oprea, T. I. (2002). Virtual screening in lead discovery: a viewpoint. Molecules, 7(1), 51-62.
6. Ezenyi, I. C., & Salawu, O. A. (2016). Approaches, challenges and prospects of antimalarial drug discovery from plant sources. IntechOpen.
7. Simonsen, J. (2009). A Concern for Engaged Scholarship: The challenges for action research projects. Scandinavian Journal of Information Systems, 21(2), 1.
8. Nevola, L., & Giralt, E. (2015). Modulating protein–protein interactions: the potential of peptides. Chemical Communications, 51(16), 3302-3315.
9. Seyhan, A. A. (2019). Lost in translation: the valley of death across preclinical and clinical divide–identification of problems and overcoming obstacles. Translational Medicine Communications, 4(1), 1-19.
10. Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016). Twenty years on: the impact of fragments on drug discovery. Nature reviews Drug discovery, 15(9), 605-619.
11. Nicholson, J. K., Connelly, J., Lindon, J. C., & Holmes, E. (2002). Metabonomics: a platform for studying drug toxicity and gene function. Nature reviews Drug discovery, 1(2), 153-161.
12. Kraljevic, S., Stambrook, P. J., & Pavelic, K. (2004). Accelerating drug discovery. EMBO reports, 5(9), 837–842.
13. Jorgensen W. L. (2004). The many roles of computation in drug discovery. Science (New York, N.Y.), 303(5665), 1813–1818.
14. Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023). The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. Pharmaceuticals (Basel, Switzerland), 16(6), 891.
15. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. Drug discovery today, 26(1), 80.
16. Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021). Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular diversity, 25, 1315-1360.
17. Blanco-Gonzalez, A., Cabezon, A., Seco-Gonzalez, A., Conde-Torres, D., Antelo-Riveiro, P., Pineiro, A., & Garcia-Fandino, R. (2023). The role of ai in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals, 16(6), 891.
18. Oliveira, A. L. (2019). Biotechnology, big data and artificial intelligence. Biotechnology journal, 14(8), 1800613.
19. Berger, S. I., & Iyengar, R. (2009). Network analyses in systems pharmacology. Bioinformatics, 25(19), 2466-2472.
20. Quazi S. (2022). Artificial intelligence and machine learning in precision and genomic medicine. Medical oncology (Northwood, London, England), 39(8), 120.
21. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics, 15(7), 1916.
22. Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020). A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery. European journal of medicinal chemistry, 195, 112275.
23. Aliper, A., Plis, S., Artemov, A., Ulloa, A., Mamoshina, P., & Zhavoronkov, A. (2016). Deep Learning Applications for Predicting

Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. Molecular pharmaceutics, 13(7), 2524–2530.

24. Gurgula O. (2020). Strategic Patenting by Pharmaceutical Companies - Should Competition Law Intervene?. IIC; international review of industrial property and copyright law, 51(9), 1062–1085.
25. Katiyar, C., Gupta, A., Kanjilal, S., & Katiyar, S. (2012). Drug discovery from plant sources: An integrated approach. Ayu, 33(1), 10–19.
26. Mould, D. R., & Upton, R. N. (2012). Basic concepts in population modeling, simulation, and model-based drug development. *CPT: pharmacometrics & systems pharmacology*, *1*(9), 1-14.
27. Late-stage failures caused by unexpected toxicities can be both financially burdensome and damaging to the health of the patient
28. Bohr, A., & Memarzadeh, K. (2020). The rise of artificial intelligence in healthcare applications. In *Artificial Intelligence in healthcare* (pp. 25-60). Academic Press.
29. Basile, A. O., Yahi, A., & Tatonetti, N. P. (2019). Artificial intelligence for drug toxicity and safety. *Trends in pharmacological sciences*, *40*(9), 624-635.
30. Ankley, G. T., Bennett, R. S., Erickson, R. J., Hoff, D. J., Hornung, M. W., Johnson, R. D., ... & Villeneuve, D. L. (2010). Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. *Environmental Toxicology and Chemistry: An International Journal*, *29*(3), 730-741.
31. Park, B. K., Boobis, A., Clarke, S., Goldring, C. E., Jones, D., Kenna, J. G., ... & Baillie, T. A. (2011). Managing the challenge of chemically reactive metabolites in drug development. *Nature Reviews Drug Discovery*, *10*(4), 292-306.
32. Benfenati, E., Benigni, R., Demarini, D. M., Helma, C., Kirkland, D., Martin, T. M., ... & Yang, C. (2009). Predictive models for carcinogenicity and mutagenicity: frameworks, state-of-the-art, and perspectives. *Journal of Environmental Science and Health Part C*, *27*(2), 57-90.
33. Akacha, M., Bretz, F., & Ruberg, S. (2017). Estimands in clinical trials–broadening the perspective. *Statistics in medicine*, *36*(1), 5-19.
34. New, J. (2023). Data-driven innovation in clinical pharmaceutical research.
35. Meskó, B., & Görög, M. (2020). A short guide for medical professionals in the era of artificial intelligence. *NPJ digital medicine*, *3*(1), 126.
36. Hickman, S. E., Baxter, G. C., & Gilbert, F. J. (2021). Adoption of artificial intelligence in breast imaging: evaluation, ethical constraints and limitations. *British journal of cancer*, *125*(1), 15-22.
37. Van der Schaar, M., Alaa, A. M., Floto, A., Gimson, A., Scholtes, S., Wood, A., ... & Ercole, A. (2021). How artificial intelligence and machine learning can help healthcare systems respond to COVID-19. *Machine Learning*, *110*, 1-14.
38. Mitchell, M., Wu, S., Zaldivar, A., Barnes, P., Vasserman, L., Hutchinson, B., ... & Gebru, T. (2019, January). Model cards for model reporting. In *Proceedings of the conference on fairness, accountability, and transparency* (pp. 220-229).
39. Zhong, N. N., Wang, H. Q., Huang, X. Y., Li, Z. Z., Cao, L. M., Huo, F. Y., ... & Bu, L. L. (2023, July). Enhancing Head and Neck Tumor Management with Artificial Intelligence: Integration and Perspectives. In *Seminars in Cancer Biology*. Academic Press.
40. Bohr, A., & Memarzadeh, K. (2020). The rise of artificial intelligence in healthcare applications. In *Artificial Intelligence in healthcare* (pp. 25-60). Academic Press.
41. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. *Nature reviews drug discovery*, *20*(2), 101-124.
42. Ensom, M. H., Chang, T. K., & Patel, P. (2001). Pharmacogenetics: the therapeutic drug monitoring of the future?. *Clinical pharmacokinetics*, *40*, 783-802.
43. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. *Nature reviews drug discovery*, *20*(2), 101-124.

44. David, L., Thakkar, A., Mercado, R., & Engkvist, O. (2020). Molecular representations in AI-driven drug discovery: a review and practical guide. *Journal of Cheminformatics*, *12*(1), 1-22.
45. Acosta, J. N., Falcone, G. J., Rajpurkar, P., & Topol, E. J. (2022). Multimodal biomedical AI. *Nature Medicine*, *28*(9), 1773-1784.
46. Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017). KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic acids research*, *45*(D1), D353-D361.
47. Boeck, L., Burbaud, S., Skwark, M., Pearson, W. H., Sangen, J., Wuest, A. W., ... & Andres Floto, R. (2022). Mycobacterium abscessus pathogenesis identified by phenogenomic analyses. *Nature Microbiology*, *7*(9), 1431-1441.
48. Groves, P., Kayyali, B., Knott, D., & Kuiken, S. V. (2016). The'big data'revolution in healthcare: Accelerating value and innovation.
49. Trotta, F., Leufkens, H. G., Schellens, J. H., Laing, R., & Tafuri, G. (2011). Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. *J Clin Oncol*, *29*(16), 2266-2272.
50. Mockute, R., Desai, S., Perera, S., Assuncao, B., Danysz, K., Tetarenko, N., ... & Mingle, E. (2019). Artificial intelligence within pharmacovigilance: a means to identify cognitive services and the framework for their validation. *Pharmaceutical medicine*, *33*, 109-120.
51. Wirtz, B. W., Weyerer, J. C., & Sturm, B. J. (2020). The dark sides of artificial intelligence: An integrated AI governance framework for public administration. *International Journal of Public Administration*, *43*(9), 818-829.
52. Ryan, P., & Brennan, R. (2022). Support for enhanced GDPR accountability with the common semantic model for ROPA (CSM-ROPA). *SN Computer Science*, *3*(3), 224.
53. Vrana, J., & Singh, R. (2021). Cyber-physical loops as drivers of value creation in NDE 4.0. *Journal of Nondestructive Evaluation*, *40*(3), 61.
54. Shneiderman, B. (2020). Bridging the gap between ethics and practice: guidelines for reliable, safe, and trustworthy human-centered AI systems. *ACM Transactions on Interactive Intelligent Systems (TiiS)*, *10*(4), 1-31.
55. Wamba-Taguimdje, S. L., Fosso Wamba, S., Kala Kamdjoug, J. R., & Tchatchouang Wanko, C. E. (2020). Influence of artificial intelligence (AI) on firm performance: the business value of AI-based transformation projects. *Business Process Management Journal*, *26*(7), 1893-1924.